A Study of SHR-A1811 in Subjects With Gynaecologic Oncology

Inclusion Criteria: 1. The subjects voluntarily joined the study and signed the ICF. 2. Measurable disease, as defined by RECIST v1.1. 3. The Eastern Cancer Cooperative Group (ECOG) performance status of 0 or 1. 4. Life expectancy ≥ 12 weeks. 5. Subjects with advanced cervical cancer, recurrent ovarian cancer and endometrial cancer. Exclusion Criteria: 1. Symptomatic, untreated or active central nervous system metastases. 2. Previously received antibo-conjugated drugs with the following characteristics: topoisomerase I inhibition in the composition Preparations, such as Enhertu (DS-8201a), U3-1402, etc.. 3. Have uncontrolled or severe cardiovascular disease. 4. With any active autoimmune disease or history of autoimmune disease. 5. Patients with active hepatitis B or hepatitis C. 6. Severe infections within 28 days prior to initiation of study treatment. 7. Active tuberculosis within one year prior to initiation of study treatment.